Clinical Trials Logo

Clinical Trial Summary

In this comparative bioavailability and in vivo skin adhesion study, the impact of minor changes in qualitative composition of polyiso-Butylenes (PIB) from a different supplier and change of the manufacturing line of the micro porous membrane will be tested.


Clinical Trial Description

This study is a randomized, single-center, cross-over, comparative bioavailability and adhesion study, comparing single administrations of a new scopolamine transdermal delivery system formulation to the current established reference transdermal delivery system in healthy adult participants. The study will consist of an ambulant screening day within 21 days prior to the first investigational medicinal product (IMP) administration at study Day 1 and two treatment periods. Each treatment period will consist of 4.5 days (108 hours) of in-house confinement. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02839135
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date May 13, 2016
Completion date August 10, 2016

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Recruiting NCT06128707 - Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
Completed NCT05611814 - Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms N/A
Recruiting NCT06106256 - Three-Axis Wearable Adaptive Vestibular Stimulator N/A
Completed NCT04420949 - Sensory Training for Visual Motion Sickness N/A
Completed NCT04184115 - Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness Phase 3
Completed NCT03988530 - Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Phase 3
Terminated NCT04219982 - DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness Phase 2/Phase 3
Terminated NCT02155309 - Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Phase 2/Phase 3
Completed NCT04947423 - Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion Phase 3
Recruiting NCT05903924 - Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Recruiting NCT04999449 - Nebulizer Delivery of Intranasal Scopolamine Phase 1
Recruiting NCT05886660 - Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance Phase 2
Completed NCT03755596 - Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness Phase 4
Recruiting NCT05628220 - Motion Sickness Desensitization Using VR N/A
Recruiting NCT06138613 - Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Phase 3
Completed NCT04327661 - Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Phase 3
Completed NCT06232785 - Gynecologic Endoscopic Surgery of Female Motion Sickness Patients Phase 4
Completed NCT06056622 - Motion Sickness Rehabilitation for Virtual Reality N/A
Withdrawn NCT04331561 - Sensory Training for Orientation and Balance N/A